共 104 条
[1]
Fan L(2014)Breast cancer in China Lancet Oncol 15 e279-e289
[2]
Strasser-Weippl K(2016)Cancer statistics in China, 2015 CA Cancer J Clin 66 115-132
[3]
Li JJ(2016)Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence Breast Cancer Res Treat 159 395-406
[4]
Chen W(2014)US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status J Natl Cancer Inst 386 1341-1352
[5]
Zheng R(2015)Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials Lancet 30 1194-1220
[6]
Baade PD(2019)Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† Ann Oncol 156 81-89
[7]
Li T(2016)Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study Breast Cancer Res Treat 165 573-583
[8]
Mello-Thoms C(2017)Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial Breast Cancer Res Treat 21 6479-330
[9]
Brennan PC(2020)Targeting cell cycle in breast cancer: CDK4/6 inhibitors Int J Mol Sci 12 321-69507
[10]
Howlader N(2018)Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer Drug Des Devel Ther 8 69493-331